The Cost-Effectiveness of Canagliflozin (CANA) Versus Dapagliflozin (Dapa) 10mg and Empagliflozin (EMPA) 25mg in Patients with Type 2 Diabetes Mellitus (T2DM) as Monotherapy in the United Kingdom
Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.2098
https://www.valueinhealthjournal.com/article/S1098-3015(15)04174-1/fulltext
Section Title :
Research Podium Presentations - Session 1 and Session 2
Section Order :
1510
First Page :
A607
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04174-1&doi=10.1016/j.jval.2015.09.2098